names of glp-1 Comparing Ozempic, Wegovy and Other Drugs What to Know About GLP-1s

Scientific References Mounjaro - Assessment report

Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X, et al

Clinical trials show semaglutide produces an average of ~15% body weight loss at 68 weeks, while tirzepatide has demonstrated up to 20.9% weight loss at 72 weeks. Patients in our medical weight loss program which include nutrition and muscle preservation support lose an average of 1520% of their excess body weight on injectable GLP-1 medications, which is clinically meaningful and can improve conditions like type 2 diabetes, high blood pressure, and sleep apnea

It has a small amount of protein and is relatively low in fat, making it a healthier alternative to many other snacks

For some, staying on a lower maintenance dose for long-term success is a viable option